Caprock Group, Inc. Puma Biotechnology, Inc. Transaction History
Caprock Group, Inc.
- $4.08 Billion
- Q3 2025
A detailed history of Caprock Group, Inc. transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Caprock Group, Inc. holds 11,768 shares of PBYI stock, worth $58,251. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,768
Previous 13,817
14.83%
Holding current value
$58,251
Previous $40,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PBYI
# of Institutions
133Shares Held
35.9MCall Options Held
288KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...